Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric...

Area of Science:

• Cardiovascular Surgery
• Pediatric Cardiology
• Biomaterials Science

Background:

• Cardiopulmonary bypass (CPB) can trigger inflammatory responses in children.
• The inflammatory side effects of CPB are a significant concern in pediatric cardiac surgery.
• Heparin-coated circuits are known to improve biocompatibility in adults.

Purpose of the Study:

• To evaluate the efficacy of heparin-coated CPB circuits in mitigating inflammatory responses in pediatric patients.
• To determine if the biocompatibility benefits observed in adults extend to children undergoing cardiac surgery.
• To compare the inflammatory markers in children randomized to heparin-coated versus standard CPB circuits.

Main Methods:

• A randomized controlled trial involving 19 pediatric patients undergoing cardiac surgery.
• Patients were assigned to either heparin-coated (HC) or standard (C) CPB circuits (n=10 each).
• Plasma levels of acute phase reactants, interleukins, granulocytic proteins, and complement factors were measured post-CPB.

Main Results:

• All measured inflammatory markers were elevated after CPB in both groups.
• Significantly lower levels of complement factor C3a, Terminal Complement Complex, and interleukin-6 were observed in the heparin-coated group (p < 0.001 for C3a and TCC, p = 0.005 for IL-6).
• Heparin-coated circuits demonstrated improved biocompatibility, indicated by reduced inflammatory mediator levels.

Conclusions:

• Heparin-coated CPB circuits are effective in improving biocompatibility during heart surgery in pediatric patients.
• The use of heparin-coated circuits leads to significantly reduced levels of circulating complement factors and interleukin-6.
• These findings suggest that heparin-coated CPB circuits are a beneficial option for minimizing inflammatory complications in pediatric cardiac surgery.